scholarly journals Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited

Cureus ◽  
2022 ◽  
Author(s):  
Leonardo P Suciadi ◽  
Joshua Henrina ◽  
Iwan Cahyo Santosa Putra ◽  
Irvan Cahyadi ◽  
Hoo Felicia Hadi Gunawan
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Homeostasis ◽  
Clinical Implications

scholarly journals Iron Deficiency as a Therapeutic Target in Cardiovascular Disease

2019 ◽  
Vol 12 (3) ◽  
pp. 125 ◽  
Author(s):  
Samira Lakhal-Littleton
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Iron Supplementation ◽  
Iron Homeostasis ◽  
Iron Regulatory Proteins ◽  
Cellular Iron ◽  
Cellular Iron Homeostasis

Iron deficiency is the most common nutritional disorder in the world. It is prevalent amongst patients with cardiovascular disease, in whom it is associated with worse clinical outcomes. The benefits of iron supplementation have been established in chronic heart failure, but data on their effectiveness in other cardiovascular diseases are lacking or conflicting. Realising the potential of iron therapies in cardiovascular disease requires understanding of the mechanisms through which iron deficiency affects cardiovascular function, and the cell types in which such mechanisms operate. That understanding has been enhanced by recent insights into the roles of hepcidin and iron regulatory proteins (IRPs) in cellular iron homeostasis within cardiovascular cells. These studies identify intracellular iron deficiency within the cardiovascular tissue as an important contributor to the disease process, and present novel therapeutic strategies based on targeting the machinery of cellular iron homeostasis rather than direct iron supplementation. This review discusses these new insights and their wider implications for the treatment of cardiovascular diseases, focusing on two disease conditions: chronic heart failure and pulmonary arterial hypertension.

scholarly journals Prevalence and clinical implications of liver dysfunction in chronic heart failure

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P5067-P5067
Author(s):  
M. Valentova ◽  
A. Sandek ◽  
T. Bekfani ◽  
L. Steinbeck ◽  
N. Ebner ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Liver Dysfunction ◽  
Clinical Implications

Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure

2014 ◽  
Vol 8 (4) ◽  
pp. 493-497
Author(s):  
Changzheng Gao ◽  
Qi Lu ◽  
Suxia Guo ◽  
Zhenyu Yang ◽  
Kulin Li ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Natriuretic Peptide ◽  
Poor Prognosis ◽  
High Plasma ◽  
Clinical Implications ◽  
Severe Chronic Heart Failure ◽  
Significant Difference ◽  
Group A ◽  
Group B

Abstract Background: High plasma B-type natriuretic peptide (BNP) levels in patients with severe chronic heart failure (CHF) often indicate poor ventricular function and poor prognosis. However, in some such patients plasma BNP levels are normal. Objective: To investigate the clinical implications of BNP levels in patients with severe CHF. Methods: Fifty-seven patients with severe CHF were divided into group A (13 normal plasma BNP level) and 44 patients (high plasma BNP levels) group B. Diuretics, angiotensin-converting enzyme inhibitors (or angiotensin II receptor antagonist, e.g., metoprolol) and digitalis were used as conventional treatment. The clinical characteristics of all patients in two groups were analyzed and compared. Results: At the first admission, left ventricular end diastolic diameter in group B was significantly lower than group A (p < 0.05), and the plasma BNP level in group B was significantly higher than group A (p < 0.05). When metoprolol was used, 6 and 5 patients in group A and B could not tolerate the initial dose. In other cases using metoprolol at average maximum tolerance dose of metoprolol 12.5-6.25 and 24.20-11.22 mg/day in group A and B, respectively, there was a significant difference between them (p < 0.05). There were no significant differences in plasma BNP levels between two groups during stable period. The plasma BNP level in group B during acute worsening stage was significantly higher than in the remission stage (962.73-165.00 ng/L vs 876.24-167.70 ng/L, p < 0.05). However, there was no significant difference between group A (74.03-11.18 ng/L) and group B (71.38-11.68 ng/L) (p > 0.05). The mobility of group A was higher than group B (11/12 vs 6/44, p < 0.05). Logistic regression analysis showed that, the plasma BNP level was the independent risk factor for predicting cardiac death (regression coefficient, 3.817; OR, 45.488; 95% CI, 5.322ʺ388.791). Conclusion: In patients with severe CHF, normal plasma BNP level suggests depletion of BNP secretion and further deterioration of cardiac function, indicating a poor prognosis.

scholarly journals Clinical Implications of Chronic Heart Failure Phenotypes Defined by Cluster Analysis

2014 ◽  
Vol 64 (17) ◽  
pp. 1765-1774 ◽  
Author(s):  
Tariq Ahmad ◽  
Michael J. Pencina ◽  
Phillip J. Schulte ◽  
Emily O’Brien ◽  
David J. Whellan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cluster Analysis ◽  
Chronic Heart Failure ◽  
Clinical Implications

Myocardial iron homeostasis in advanced chronic heart failure patients

2012 ◽  
Vol 159 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Przemysław Leszek ◽  
Barbara Sochanowicz ◽  
Małgorzata Szperl ◽  
Piotr Kolsut ◽  
Kamil Brzóska ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Iron Homeostasis ◽  
Myocardial Iron ◽  
Heart Failure Patients

Tumour markers in chronic heart failure. Review of the literature and clinical implications

2006 ◽  
Vol 7 (8) ◽  
pp. 573-579 ◽  
Author(s):  
Pompilio Faggiano ◽  
Antonio DʼAloia ◽  
Francesco Antonini-Canterin ◽  
Enrico Vizzardi ◽  
Gian Luigi Nicolosi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Tumour Markers ◽  
Clinical Implications ◽  
Review Of The Literature
Sign in / Sign up

Export Citation Format

Share Document